More than fifty lawmakers just sent a blunt message to Dr. Mehmet Oz at the Centers for Medicare and Medicaid Services. Drop your proposed drug pricing policy before you wreck innovation in cancer treatment. And here’s the kicker: this isn’t some partisan squabble. Democrats and Republicans alike are telling the Trump administration that this particular rule needs to die.
The proposal sits at the messy intersection of two administrations’ policies. Biden signed the Inflation Reduction Act back in 2022, creating Medicare’s Drug Price Negotiation Program. Fair enough. But now the Trump team is trying to implement it, and they’ve added a wrinkle that’s got everyone nervous. The so-called fixed-dose combination policy would slam newer versions of existing drugs into price negotiations almost immediately after FDA approval.
You know what that means? Pharmaceutical companies would face negotiated prices before they could recoup development costs on improved medicines. The lawmakers aren’t being subtle about the consequences either. They’re saying flat out that this will discourage drugmakers from creating better treatments.
Let’s talk about what “better” actually means here. We’re not discussing minor tweaks or cosmetic changes. The letter specifically mentions advances in cancer immunotherapy that transformed treatments requiring hours of intravenous infusion into quick injections. That’s not marketing spin. That’s a genuine improvement in quality of life for people fighting cancer, especially those living far from major medical centers.
Rural patients shouldn’t have to spend entire days getting treatment when a subcutaneous injection could do the job. But developing these improvements costs real money and takes years of clinical trials. The FDA already treats these therapies as separate medicines requiring their own approval process. So why would CMS treat them differently for pricing purposes?
The administration’s logic is understandable, honestly. They’re worried about pharmaceutical companies gaming the system by making tiny changes to dodge price negotiations. That’s a legitimate concern. Nobody wants to see drugmakers slapping new labels on old products just to reset the clock on Medicare pricing. But Congress is saying this policy throws out the baby with the bathwater.
Here’s where it gets interesting. The lawmakers point out that CMS’s own actuaries couldn’t demonstrate meaningful savings from this policy. So we’re talking about potentially crushing innovation without even achieving significant cost reductions. That’s not conservative policy. That’s just bad policy.
Limited government means getting out of the way when markets can solve problems better than bureaucrats. And the pharmaceutical market, for all its flaws, does respond to incentives. Take away the incentive to develop improved treatments and you’ll get fewer improved treatments. Economics 101.
The fixed-dose combination policy exemplifies what happens when well-intentioned cost control measures collide with medical innovation. Yes, drug prices matter. Yes, Medicare spending needs oversight. But there’s a difference between negotiating prices on existing drugs and accidentally creating a system that discourages the development of genuinely better therapies.
Dr. Oz inherited a complicated situation. The Inflation Reduction Act passed before Trump returned to office, and now his administration has to make it work. But making it work doesn’t require finalizing every proposed rule that comes down the pike. Sometimes the right call is recognizing when a policy will cause more harm than good.
The bipartisan nature of this pushback matters too. When both parties agree something’s wrong, it’s worth paying attention. Congress doesn’t accidentally unite on healthcare policy. These lawmakers represent different constituencies with different priorities, yet they all arrived at the same conclusion about this rule.
Cancer patients deserve access to the most advanced therapies available. Rural Americans shouldn’t face worse treatment options because of where they live. And pharmaceutical companies need reasonable incentives to keep developing better medicines. None of these principles conflict with conservative values. They reinforce them.
The Trump administration still has time to pull this policy before finalizing the rule. That’s what the lawmakers are asking for, and it’s the right move. You don’t have to love Big Pharma to recognize that innovation requires investment and investment requires return. Kill the return and you kill the innovation. Then everybody loses, especially the patients who need tomorrow’s treatments.
Related: New Federal Policy Treats Unborn Children as Foster Care Candidates